DEA administrative hearing remains suspended as rescheduling enters fourth month without movement
Despite Trump's December executive order directing expedited rescheduling, the DEA has yet to appoint a new administrative law judge. Congressional opposition from 48 GOP lawmakers adds uncertainty to the timeline.
Four months after President Trump signed an executive order directing the "most expeditious" rescheduling of marijuana, the process has not moved. The DEA's administrative hearing — the key procedural step standing between the current proposed rule and a final decision — remains suspended with no date set for resumption.
Where things stand
The hearing was suspended before Trump's executive order was signed. Chief Administrative Law Judge John Mulrooney halted proceedings pending an interlocutory appeal on procedural questions raised by hearing participants. Since then, no new administrative law judge has been appointed to take over the case.
The executive order, signed December 18, 2025, directed the Attorney General and DEA to move rescheduling forward as quickly as legally possible. But executive orders cannot override the Administrative Procedure Act's requirements for notice-and-comment rulemaking. The process has a fixed sequence that cannot be shortcut by presidential directive.
The political landscape
Attorney General Pam Bondi has been notably quiet on the issue. As Florida's Attorney General, Bondi was a vocal opponent of marijuana legalization, and observers have noted her lack of public statements on rescheduling since taking office.
On Capitol Hill, 48 Republican lawmakers have signed letters opposing rescheduling, arguing that it would undermine existing drug enforcement frameworks and send the wrong message on substance abuse policy. Their opposition doesn't directly block the administrative process, but it signals the political headwinds facing any final rule.
The rulemaking timeline
The current rescheduling effort has been years in the making:
- August 2023 — The Department of Health and Human Services formally recommended that marijuana be moved from Schedule I to Schedule III, marking the first time a federal health agency acknowledged marijuana's accepted medical use
- May 2024 — The DEA published a proposed rule to implement the rescheduling
- August 2024 — The public comment period closed with more than 42,000 submissions
Legal experts say a final rule remains far from imminent. "This is a years-long effort, not a months-long one," according to cannabis law practitioners who have tracked the process. The administrative hearing alone, once resumed, could take months to complete.
What Schedule III means — and doesn't
Even if rescheduling is finalized, marijuana would remain a federally controlled substance. Schedule III classification — the same category as Tylenol with codeine and anabolic steroids — carries significant implications but falls well short of legalization.
What would change:
- Elimination of the Section 280E tax burden, which currently prevents marijuana businesses from deducting ordinary business expenses
- Easier pathways for clinical research involving cannabis
- A formal federal acknowledgment of marijuana's accepted medical use
- Reduced stigma in healthcare and employment contexts
What would not change:
- Interstate commerce would remain prohibited
- Full banking access (the SAFER Banking Act) would still require separate legislation
- State-level marijuana program structures would remain unchanged
- Recreational use would still be governed entirely by state law
What to watch
The next meaningful development will be the appointment of an administrative law judge to resume the hearing, or a decision by the DEA to bypass the hearing process entirely — a legally risky move that would almost certainly face court challenge. Until then, rescheduling remains frozen in procedural limbo despite the executive order's urgency.